The Food and Drug Administration on Tuesday approved

美国食品药品监督管理局周二批准

Ozempic,

限制，

the weight loss drug made by

减肥药由

Novo Nordisk A/S

诺和诺德公司

NVO

非政府 组织

, for the treatment of chronic kidney disease in patients who also

，用于治疗慢性肾脏疾病的患者

have type 2 diabetes.

患有2型糖尿病。

The Details:

详细信息：

According to the Centers for Disease Control and Prevention, more than 35.5 million Americans have chronic kidney disease, often as a complication of type 2 diabetes. The new FDA approval allows for further expansion of Ozempic's use and potential coverage by health insurance plans.

根据疾病控制和预防中心的数据，超过3550万美国人患有慢性肾脏疾病，通常是2型糖尿病的并发症。。

Read Next:

阅读下一页：

SoFi Stock Falls On Soft Guidance Despite ‘Strong Quarter’ With Record Member Growth, Loan Originations: Analyst

分析师表示，尽管“强劲季度”成员增长创纪录，但SoFi股票在软指导下下跌

The FDA approval 'allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of adults and could have serious consequences if left untreated,'

FDA的批准“使我们能够更广泛地解决心血管肾脏代谢综合征的疾病，这种疾病会影响数百万成年人，如果不及时治疗，可能会产生严重后果。”

Anna Windle

安娜·温德尔

, a senior vice president at Novo Nordisk, said in a statement Tuesday, per a Bloomberg

据彭博社报道，诺和诺德高级副总裁在周二的一份声明中表示

report

报告

.

.

Ozempic and other diabetes drugs known as GLP-1s have become popular and also well-known for their high cost.

。

Earlier in January, Novo Nordisk's diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy were all added to the U.S. Department of Health and Human Services list of drugs covered under Medicare Part D that

1月初，诺和诺德的糖尿病和减肥药Ozempic、Rybelsus和Wegovy都被添加到美国卫生与公众服务部的Medicare D部分药物清单中

have been selected

已选定

for mandated price negotiations in order to reduce

进行强制性价格谈判，以减少

prescription drug costs

处方药费用

.

.

The negotiations will take place in 2025, with the new prices slated to take effect in 2027.

。

NVO Price Action:

NVO价格行动：

According to

根据

Benzinga Pro

Benzinga Pro 的

, Novo Nordisk shares ended Tuesday's session down 2.65% at $85.19.

诺和诺德股价周二收盘下跌2.65%，至85.19美元。

Read Next:

阅读下一页：

Microsoft Q2 Earnings Preview: Street ‘Too Optimistic’ On Near-Term AI Returns?

微软第二季度盈利预览：华尔街对近期人工智能回报“过于乐观”？

Photo: Shutterstock

NVO

非政府 组织

Novo Nordisk AS

诺和诺德公司

$85.50

$85.50

-2.30

-2.30

%

%

Overview Rating:

概述评级：

Good

很好

62.5%

62.5%

Technicals Analysis

技术分析

66

66

0

0

100

100

Financials Analysis

财务分析

60

60

0

0

100

100

Watchlist

观察名单

Overview

概述

Market News and Data brought to you by Benzinga APIs

Benzinga API为您带来的市场新闻和数据

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

©2025 Benzinga.com。Benzinga不提供投资建议。保留所有权利。